In collaboration with the DZL
- LCSA-i - Early intervention treatment of SARS-CoV-2 with liposomal Cyclosporine A for Inhalation in non-hospitalized patients due to Covid 19 - A Prospective, Randomized, Double-Blind Phase II Trial
- GI-COVID - Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Inhalation to prevent ARDS in COVID-19 pneumonia
The scope of this trial is to improve host defense of the lung and at the same time drive repair of the injured organ in hospitalized patients with COVID-19 pneumonia by inhalation of granulocyte-macrophage colony stimulating factor (GM-CSF; Molgramostim), a cytokine that has been shown to exert both of these effects in the lung. This study is funded by the BMBF as part of the "Nationales Forschungsnetz zoonotische Infektionskrankheiten"
read more (in german)
- GI-Hope - https://clinicaltrials.gov/ct2/show/NCT02595060?term=GI+HOPE&rank=1
This trial evaluates efficacy and safety of inhaled molgramostim (rhGM-CSF) in 45 patients with community-associated pneumonia (CAP)-related acute respiratory distress syndrome (ARDS).
A third of the patients will receive 150 mcg inhaled molgramostim, another third 450 mcg and the remaining third will receive inhaled placebo for 3 days. The patients will be followed for 28 days.
read more (in german)
In collaboration with the German Center for Infection Research DZIF
R-Net investigates the effect of various interventions aimed at limiting the spread of infections due to multi-drug resistant organisms (MDRO) – including infection prevention and control, decolonization, antimicrobial stewardship (AMS) and the development of new antimicrobials active against MDRO. Key epidemiological, microbiological, and clinical background data on multi-drug resistant pathogens will be collected over a period of four years at six DZIF partner sites.
Bloodstream infections (BSI) are associated with high morbidity and mortality worldwide and are still considered as one of the most severe bacterial infections. The BLOOMY-PREDICT project is an observational study, which runs at five German university hospitals. Within the scope of the project, different clinical values of patients such as previous illnesses, certain blood values or data on the course of treatment are combined to form a so-called clinical score. With the help of this score, patient groups with a higher risk of long-term consequences can in future receive additional diagnostics, more intensive therapy schedules, increased monitoring and closer follow-up checks after discharge from hospital.
In collaboration with the Network University Medicine NUM
Multicenter prospective study to determine the immune response and the immunophenotyp in population of special risk (e.g. health care workers, patients after organ transplantation) after SARS-CoV-2 vaccination.